News

MAR 31 2020
ALL ARTICLES

Business Continuity during Covid19

Posted by: Gary Hill in research

Dear Valued Partners, Stakeholders, and Industry Colleagues,

Pharmaceutical Solutions expresses our support and empathy for
global communities, organisations, and individuals impacted by COVID-19. Our
focus at this time will remain on providing service to our sponsors and
supporting our clients in their vital work, as well as ensuring the safety of
our staff.

We’ve
written this open letter to provide you with information and details on our
initiatives, which outline Pharmaceutical Solutions’ response to the situation
around COVID-19.

Our
initiatives encompass the areas of business continuity, management planning,
staff safety, and project continuity.
We are taking precautions to protect our
team and their families, our partners, clients, sponsors, as well as our wider
network of colleagues and associates from the impact of this global health
crisis.

As the COVID-19 situation evolves, we will continue to communicate changes within
the Pharmaceutical Solutions (PSL) environment.

Business Continuity:

Our business continuity plan (BCP) identifies actions essential to the continued
delivery of services. We are focused on ensuring the continuation of a high
standard of service to our partners.

·        
All staff are working from home. 

·        
All systems used by PSL are cloud-based with high levels of
security, disaster backup, and recovery processes.

·        
Our office communication systems have been diverted

Staff Safety:

The health and safety of our employees, their families, and our clients and
partners is our paramount focus. During level 4, lock-down PSL will follow
Government requirements. During subsequent levels the following measures will
be in place:

·        
We have restricted visitor access to our Auckland office

·        
We require staff who have traveled internationally to follow government
guidelines and self-isolate for 14 days

·        
We have offered all office-based staff the option to work from home

·        
We have equipped our office with surface and hand sanitizers

·        
We have offered all staff influenza vaccinations to minimize the risk of dual
exposure – recognising the upcoming southern hemisphere flu season

Management planning:

COVID-19
planning is now an essential part of our weekly Executive Committee meetings.
Our aims for these meetings are to ensure:

·        
We minimise risks to staff in our working environment

·        
We understand site impacts and can create a contingency for our clients


We will continue to govern the company to the highest level.

·        
We understand impacts concerning regulatory authorities, ethics committees,
important authorities.

Project Continuity:

·        
We are currently collating a register of any issues with site availability, and
project managers are creating contingency plans in case of site closures.

·        
We are continually assessing the impact concerning regulatory authorities,
ethics committees, importation authorities, etcetera

·        
We have reviewed and updated the PSL’s remote monitoring SOP as clients and sites
are increasingly supporting remote monitoring.

·        
We are initiating fast conferencing capabilities as we expect that a number of
meetings will need to change the format.

The Pharmaceutical Solutions team recognises COVID-19 as an unprecedented global
scenario. Without a doubt, it will necessitate the creation of novel ways to
work in clinical trial management. Our employees are meeting business
objectives, bringing world-class expertise to our clients, and will continue to
do so.

On behalf of Pharmaceutical Solutions, we extend our gratitude to our stakeholders
and satellite organisations for their ongoing relationship with us. We are
committed to staying connected and supportive during this period of uncertainty.

Please do not hesitate to contact me or your Pharmaceutical Solutions project team if
you have any questions.

Kind regards

Jacquie Palmer Managing Director 

Tags: Clinical Studies, Project Management,

Dear Valued Partners, Stakeholders, and Industry Colleagues,

Pharmaceutical Solutions expresses our support and empathy for
global communities, organisations, and individuals impacted by COVID-19. Our
focus at this time will remain on providing service to our sponsors and
supporting our clients in their vital work, as well as ensuring the safety of
our staff.

We’ve
written this open letter to provide you with information and details on our
initiatives, which outline Pharmaceutical Solutions’ response to the situation
around COVID-19.

Our
initiatives encompass the areas of business continuity, management planning,
staff safety, and project continuity.
We are taking precautions to protect our
team and their families, our partners, clients, sponsors, as well as our wider
network of colleagues and associates from the impact of this global health
crisis.

As the COVID-19 situation evolves, we will continue to communicate changes within
the Pharmaceutical Solutions (PSL) environment.

Business Continuity:

Our business continuity plan (BCP) identifies actions essential to the continued
delivery of services. We are focused on ensuring the continuation of a high
standard of service to our partners.

·        
All staff are working from home. 

·        
All systems used by PSL are cloud-based with high levels of
security, disaster backup, and recovery processes.

·        
Our office communication systems have been diverted

Staff Safety:

The health and safety of our employees, their families, and our clients and
partners is our paramount focus. During level 4, lock-down PSL will follow
Government requirements. During subsequent levels the following measures will
be in place:

·        
We have restricted visitor access to our Auckland office

·        
We require staff who have traveled internationally to follow government
guidelines and self-isolate for 14 days

·        
We have offered all office-based staff the option to work from home

·        
We have equipped our office with surface and hand sanitizers

·        
We have offered all staff influenza vaccinations to minimize the risk of dual
exposure – recognising the upcoming southern hemisphere flu season

Management planning:

COVID-19
planning is now an essential part of our weekly Executive Committee meetings.
Our aims for these meetings are to ensure:

·        
We minimise risks to staff in our working environment

·        
We understand site impacts and can create a contingency for our clients


We will continue to govern the company to the highest level.

·        
We understand impacts concerning regulatory authorities, ethics committees,
important authorities.

Project Continuity:

·        
We are currently collating a register of any issues with site availability, and
project managers are creating contingency plans in case of site closures.

·        
We are continually assessing the impact concerning regulatory authorities,
ethics committees, importation authorities, etcetera

·        
We have reviewed and updated the PSL’s remote monitoring SOP as clients and sites
are increasingly supporting remote monitoring.

·        
We are initiating fast conferencing capabilities as we expect that a number of
meetings will need to change the format.

The Pharmaceutical Solutions team recognises COVID-19 as an unprecedented global
scenario. Without a doubt, it will necessitate the creation of novel ways to
work in clinical trial management. Our employees are meeting business
objectives, bringing world-class expertise to our clients, and will continue to
do so.

On behalf of Pharmaceutical Solutions, we extend our gratitude to our stakeholders
and satellite organisations for their ongoing relationship with us. We are
committed to staying connected and supportive during this period of uncertainty.

Please do not hesitate to contact me or your Pharmaceutical Solutions project team if
you have any questions.

Kind regards

Jacquie Palmer Managing Director 

Tags: Clinical Studies, Project Management,

ALL ARTICLES